{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:44:17Z","timestamp":1791823457752,"version":"4.3.4"},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":203,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold>Collective pediatric data suggest that anti\u2010T\u2010cell induction therapy with polyclonal antibodies improves the outcome of both short\u2010 and long\u2010term renal allograft survival. Polyclonal agents, including thymoglobulin (Thy), a rabbit anti\u2010thymocyte globulin; Minnesota (horse) anti\u2010lymphoblast globulin (ALG); and ATGAM, a horse anti\u2010thymocyte globulin (ATG), all suppress B and T cells. While no specific T\u2010cell subset marker exists to measure the adequacy of immunosuppression with polyclonal induction, flow cytometric analysis has been used to evaluate the suppression of CD3, CD4, and CD8 cells. Thy is currently undergoing pediatric trials at our center, and we have utilized ATG and ALG in previous pediatric induction protocols. ALG (20\u2003mg\/kg\/day) and ATG (15\u2003mg\/kg\/day) were administered over 10\u2003days, whereas Thy (2\u2003mg\/kg\/day) was given over 5\u2003days. All inductions were accompanied by preoperative intravenous solumedrol (10\u2003mg\/kg) followed by oral prednisone (2\u2003mg\/kg\/day) with taper. Preoperative (1.5\u2003mg\/kg\/day) and post\u2010operative (2\u2003mg\/kg\/day) azathioprine was administered to patients receiving ALG or ATG. Mycophenolate mofetil (MMF) (1200\u2003mg\/m<jats:sup>2<\/jats:sup>\/day) was given to the patients receiving Thy. Post\u2010operative cyclosporin A (CsA) (14\u2003mg\/kg\/day) was started (for all groups) once renal function permitted (creatinine &lt;\u200350% of baseline with brisk urine output) (trough goal 150\u2013250\u2003ng\/mL via HPLC). Values for CD3, CD4, and CD8 T cells were determined by flow cytometry in 2\u201318\u2010yr\u2010old renal transplant recipients, comparing the polyclonal induction agent utilized [Thy (n\u2003=\u20038), mean age 9.7\u2003\u00b1\u20032.3\u2003yr; ATG (n\u2003=\u200313), mean age 10.1\u2003\u00b1\u20034.1\u2003yr; and ALG (n\u2003=\u20039), mean age 9.3\u2003\u00b1\u20033.7\u2003yr] over days 2\u201310 post\u2010induction. Data were expressed as the average percentage of cells remaining relative to the baseline T\u2010cell subsets (day 1\u2003=\u2003100%), because of the large age variation present in basal T\u2010cell subset values. The flow cytometric data suggest that 5\u2003days of Thy appears to give an equal or greater peripheral blood T\u2010cell suppression by day 10 than a 10\u2010day course of either ATG or ALG.<\/jats:p>","DOI":"10.1034\/j.1399-3046.2001.00054.x","type":"journal-article","created":{"date-parts":[[2004,12,28]],"date-time":"2004-12-28T17:05:34Z","timestamp":1104253534000},"page":"174-178","source":"Crossref","is-referenced-by-count":20,"title":["Comparison of polyclonal induction agents in pediatric renal transplantation"],"prefix":"10.1034","volume":"5","author":[{"given":"Patrick D.","family":"Brophy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"McBryde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Bunchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,4,14]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3046.1999.00011.x"},{"key":"e_1_2_7_3_2","first-page":"251","volume-title":"Primer on Transplantation","author":"Ettenger RB","year":"1999"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.990220104"},{"key":"e_1_2_7_5_2","volume-title":"First Congress of the International Pediatric Transplant Association.","author":"Bartosh SM","year":"2000"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0041-1345(97)81734-4"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199504270-00020"},{"key":"e_1_2_7_8_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1399-0012.1993.tb00905.x","article-title":"OKT3 reversal of biopsy\u2010proven allograft rejection occurring during MALG induction in the pediatric renal recipient","volume":"7","author":"Bunchman TE","year":"1993","journal-title":"Clin Transpl"},{"key":"e_1_2_7_9_2","first-page":"2817","article-title":"Monitoring of ATG therapy by flow cytometry and lymphocyte counts in renal transplantation","volume":"28","author":"Buchler M","year":"1996","journal-title":"Transplant Proc"},{"key":"e_1_2_7_10_2","unstructured":"WagnerFM TugtekinSM MatschkeK PlatzbeckerU GulielmosV SchulerS.Flow cytometry\u2010controlled induction therapy with ATG and noninvasive monitoring of rejection \u2013 a modern management concept after heart transplantation.Lagenbecks Archiv fur Chirurgie1998:Suppl. 115:1566\u20131567."},{"key":"e_1_2_7_11_2","first-page":"3214","article-title":"OKT3 prophy\u2010laxis in kidney transplant recipients: drug monitoring by flow cytometry","volume":"28","author":"Cinti P","year":"1996","journal-title":"Transplant Proc"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.3109\/08820139709048918"},{"key":"e_1_2_7_13_2","first-page":"577","article-title":"Association of sensitization to horse antilymphocyte\/thymocyte globulin with recipient age and decreased renal allograft survival rates","volume":"25","author":"Filo RS","year":"1993","journal-title":"Transplant Proc"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199811150-00016"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3046.2001.00054.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1399-3046.2001.00054.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T21:03:44Z","timestamp":1734815024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1399-3046.2001.00054.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1034\/j.1399-3046.2001.00054.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1399-3046.2001.00054.x","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}